Table 3.
Type of lipid-lowering treatment at end of follow-up.
| Primary lipid lowering therapy | Additional therapy | |||
|---|---|---|---|---|
| Intervention | Control | Intervention | Control | |
| None, n (%) | 49 (10.1) | 84 (17.6) | 382 (78.6) | 466 (97.9) |
| Simvastatin, n (%) | 56 (11.5) | 110 (23.1) | ||
| Atorvastatin, n (%) | 298 (61.3) | 256 (53.8) | ||
| Rosuvastatin, n (%) | 72 (14.8) | 19 (4.0) | ||
| Other statin, n (%) | 5 (1) | 3 (0.6) | ||
| Ezetimibe, n (%) | 6 (1.2) | 3 (0.6) | 104 (21.4) | 10 (1.2) |
| Other, n (%) | 0 | 1 (0.2) | 1 (0.2) | 0 |
| High-intensity, n (%) | 337 (69.3) | 211 (44.3) | ||
| Low/Medium-intensity, n (%) | 94 (19.3) | 177 (37.2) | ||
High-intensity: lipid-lowering therapy (simvastatin >40 mg, atorvastatin ≥40 mg or rosuvastatin >10 mg); Low/Medium-intensity: not fulfilling the above.